In 2015, ACCC launched the Institute for Clinical Immuno-Oncology, the first initiative to guide the multidisciplinary care team’s adoption of immuno-oncology (IO) in community cancer settings across the country. Since that time, IO has advanced at a rapid pace—and so has our Institute!
The Association of Community Cancer Centers (ACCC) Immuno-Oncology Institute is the leader in optimizing the delivery of cancer immunotherapies for patients by providing clinical education, advocacy, research, and practice management solutions for multidisciplinary cancer care teams across all healthcare settings.The Institute provides a platform for dynamic, multi-directional learning to:
The ACCC Immuno-Oncology Institute is guided by an expert multidisciplinary Executive Committee.
The ACCC Immuno-Oncology Institute is supported by Bristol-Myers Squibb (charitable donation); EMD Serono; Kite, a Gilead Company; and Merck & Co, Inc (educational grant).